诊断学理论与实践

诊断学理论与实践 ›› 2021, Vol. 20 ›› Issue (05): 462-465.doi: 10.16150/j.1671-2870.2021.05.007

• 论著 • 上一篇    下一篇

血清人衰老关键蛋白1检测对结肠直肠癌的诊断和预后价值

张华1, 陆炜1, 杨承翌2, 项明洁1()   

  1. 1.上海交通大学医学院附属瑞金医院卢湾分院放免检验科,上海 200020
    2.上海交通大学医学院医学检验系20届,上海 200020
  • 收稿日期:2020-10-14 出版日期:2021-10-25 发布日期:2022-06-28
  • 通讯作者: 项明洁 E-mail:mjxiang12345@126.com
  • 基金资助:
    国家自然科学基金(81871700);上海市2017年度“科技创新行动计划”产学研医合作领域项目子课题(17DZ1930301-26)

Value of serum FBLN1 detection in diagnosis and prognosis prediction of colorectal cancer

ZHANG Hua1, LU Wei1, YANG Chengyi2, XIANG Mingjie1()   

  1. 1. Department of Radioimmunoassay Center and Clinical Lab, Luwan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200020, China
    2. Shanghai Jiao Tong University School of Medicine, Medical Test of the 20th, Shanghai 200020, China
  • Received:2020-10-14 Online:2021-10-25 Published:2022-06-28
  • Contact: XIANG Mingjie E-mail:mjxiang12345@126.com

RichHTML

3

PDF (PC)

107

摘要：

目的：探究人衰老关键蛋白1（Fibulin-1, FBLN1）作为血清标志物在结肠直肠癌（colorectal cancer, CRC）诊断中的价值。 方法：选取81例CRC患者作为CRC组,50例结肠直肠息肉患者（息肉组）和50名健康体检者（健康组）作为对照,采用酶联免疫吸附试验（enzyme-linked immunosorbent assay, ELISA）检测其血清FBLN1及癌胚抗原（carcinoembryonic antigen,CEA）水平,并进行组间比较分析。 结果：与血清CEA类似,CRC组的血清FBLN1水平[（12.98±7.82） ng/mL]明显高于息肉组[（7.54±1.23） ng/mL]和健康组[（6.89±2.03） ng/mL],差异均具有统计学意义（P<0.05）,息肉组与健康组间的血清FBLN1水平差异无统计学意义。低分化CRC患者的血清FBLN1水平[（22.23±18.51） ng/mL]分别高于中分化CRC[（11.65±13.28） ng/mL,P<0.05]及高分化CRC患者[（9.12±10.17） ng/mL,P<0.05],有淋巴结转移的CRC患者的血清FBLN1水平[（15.26±6.98） ng/mL]高于无淋巴结转移的患者[（8.58±4.27） ng/mL,P<0.05]。血清FBLN1>9.85 ng/mL诊断CRC的受试者操作特征（receiver operating characteristc,ROC）曲线下面积为0.852,灵敏度为82.7%,特异度约为90.0%,均优于CEA（灵敏度64.2%,特异度为82.1%）。 结论：血清FBLN1水平有可能作为CRC诊断及判断病理分化程度、淋巴结转移情况的标志物。

关键词: 结肠直肠癌, 人衰老关键蛋白1, 癌胚抗原, 肿瘤标志物

Abstract:

Objective: To investigate the performance of serum fibulin-1 (FBLN1) detection in diagnosis and prognosis prediction of colorectal cancer. Methods: A total of 81 patients with colorectal cancer(CRC group), 50 patients with benign colorectal polyps (polyps group) and 50 healthy individuals (healthy group) were enrolled. Serum levels of FBLN1 were detected by enzyme-linked immunosorbent assay(ELISA), CEA was also measured, and difference between groups was analyzed. Results: Similar to serum CEA, serum levels of FBLN1 were significantly higher in patients with colorectal cancer [(12.98±7.82) ng/mL] than in patients with benign colorectal polyps [(7.54±1.23) ng/mL] (P<0.05) and healthy individuals [(6.89±2.03) ng/mL] (P<0.05), respectively. No significant difference were found in FBLN1 level between patients with benign colorectal polyps and healthy individuals. The serum level of FBLN1 in patients with low differentiated CRC[ (22.23±18.51) ng/mL] was higher than that in patients with medium differentiated CRC [(11.65±13.28) ng/mL] (P<0.05) and patients with high differentiated CRC[(9.12±10.17) ng/mL] (P<0.05), respectively. The serum level of FBLN1 in CRC patients with lymph node metastasis[(15.26±6.98) ng/mL] was higher than that in patients with no lymph node metastasis [(8.58±4.27) ng/mL (P<0.05). The detection of FBLN1 for diagnosing CRC had a greater AUC(0.852) than CEA,with sensitivity of 82.7% and specificity of 90.0%. Conclusions: Serum FBLN1 can serve as a biomarker for diagnosis and prognosis prediction of CRC.

Key words: Colorectal cancer, Fibulin-1, Carcinoembryonic antigen, Tumor marker

中图分类号: